



Books / Book- Chapters



CHAPTER 19

Therapeutic Potential of Small Molecules Modulating the Cyclooxygenase-5-Lipoxygenase Pathway

WOLFGANG ALBRECHT and STEFAN LAUFER

19.1 INTRODUCTION

Prostaglandins (PGs) and leukotrienes (LTs) are biologically active lipids (eicosanoids) that have been implicated in various physiological and pathophysiological processes. As one of the most important aspects, eicosanoids are involved in the regulation of several immunological responses such as cytokine production, cell proliferation, chemotaxis, and antigen presentation [1]. Pharmacological intervention into the metabolic pathway of eicosanoids represents one of the oldest and most successful therapeutic treatments. In terms of the number of prescriptions, traditional nonsteroidal antiinflammatory drugs (tNSAIDs) and gastroprotective NSAIDs, also known as the *coxibs*, are used primarily for treatment of inflammatory pain associated with osteoarthritis or rheumatic diseases, in the most widely used therapeutics. Less popular, but still achieving annual sales of more than a billion US dollars are the leukotriene antagonist montelukast (Singulair) for treatment of asthma or the prostanoïd receptor antagonists travoprost and latanoprost for treatment of glaucoma. Despite the verified efficacy of these drugs, however, they are rarely used as monotherapy. Singulair is used mainly as an add-on treatment and administered concomitantly with inhaled steroids. The prostanoïd receptor antagonists are already included in fixed-dose combinations with a β -adrenoceptor antagonists. For tNSAIDs and *coxibs*, combination therapies are frequently recommended to reduce the risk of adverse events. The coadministration of protonpump inhibitors or H₂-receptor blockers is believed to improve the gastrointestinal safety of tNSAIDs and to reduce

Polypharmacology in Drug Discovery, First Edition. Edited by Jens-Uwe Peters.
© 2012 John Wiley & Sons, Inc. Published 2012 by John Wiley & Sons, Inc.

383

Different Methods for Testing Potential Cyclooxygenase-1 and Cyclooxygenase-2 Inhibitors

Stefan Laufer and Sabine Luik

Abstract

The need for the development of selective agents, which only inhibit the mainly "harmful" cyclooxygenase-2 (COX-2) while leaving physiological COX-1 mostly unaffected, still remains, especially after the recent issues related to cardiovascular toxicity caused by some COX-2 selective agents. Thus there is still a demand for sensitive and rapid methods to assay for COX-2 selective agents. Among several in vitro testing systems the whole blood assay (WBA) is a well-known method to examine non-steroidal anti-inflammatory drugs (NSAIDs) in view of their potency to inhibit COX activity. This assay has some major advantages over enzyme-based or isolated cell assays. Emergence of artifacts due to cell separation steps is kept to a minimum and substances, even in disproportional high concentrations, can be examined outside the body in a physiological environment resembling most closely the in vivo conditions in living humans, i.e., 37°C, homeostasis, presence of all blood compounds and cell-cell interactions remain intact. While COX-1 human whole blood assays are performed within less than 2 h, for established COX-2 assays one still has to allow for an overnight incubation step before gaining the desired plasma. The aim of the assay described in this chapter is to characterize an optimized human whole blood assay (hWBA). We present a simple, fast and reliable method to examine the capacity of NSAIDs at inhibiting COX-2 activity that can be applied for rapid and routine screening purposes.

Key words: Human whole blood assay, Cyclooxygenase, Nonsteroidal antiinflammatory drugs, Drug screening


1. Introduction

Cyclooxygenase (COX) enzymes exist in two isoforms, COX-1 and COX-2. The first is expressed constitutively in many tissues, i.e., kidney (1), thrombozytes (2), and vascular endothelium (3), and contributes to the healthy state of the human body. COX-2 is the inducible isoenzyme, which is upregulated in response to cytokines, growth factors, and toxins, and displays an indicator of illnesses such as inflammation and cancer and is controversially

Samir S. Ayoub et al. (eds.), *Cyclooxygenases: Methods and Protocols*, Methods in Molecular Biology, vol. 644, DOI 10.1007/978-1-59745-964-6_8, © Springer Science+Business Media, LLC 2010

Edited by Jeremy I Levin and Stefan Laufer

Anti-Inflammatory Drug Discovery



RSCPublishing

Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases

WOLFGANG ALBRECHT^a AND STEFAN LAUFER^{*b}

^ac-a-i-r biosciences GmbH, Paul-Ehrlich Str. 15, 72076 Tübingen, Germany, Email: w.albrecht@cair-biosciences.de; ^bPharmazeutisches Institut, Eberhard-Karls-Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany

*Email: stefan.laufer@uni-tuebingen.de

5.1 Introduction

The anti-TNF α therapies represent (one of) the most successful pharmacotherapeutic options for treatment of diseases associated with chronic inflammation. Currently, TNF α antagonists (infliximab, adalimumab, etanercept, certolizumab and golimumab) are approved and widely employed for the management of moderately to severely active rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), plaque psoriasis, psoriatic arthritis and juvenile idiopathic arthritis (JIA). More than two million patients worldwide have received treatment with either one of the anti-TNF α biologic agents. Without disregarding the significant improvement for treatment of these severe and

RSC Drug Discovery Series No. 26
Anti-Inflammatory Drug Discovery
Edited by Jeremy I Levin and Stefan Laufer
© The Royal Society of Chemistry 2012
Published by the Royal Society of Chemistry, www.rsc.org

137

Topics in Medicinal Chemistry 36

Stefan Laufer *Editor*


Proteinkinase Inhibitors

Springer

Edited by Bert Klebl, Gerhard Müller,
and Michael Hamacher

WILEY-VCH

Protein Kinases as Drug Targets



Volume 49

Series Editors:
R. Mannhold,
H. Kubinyi,
G. Folkers

9

Medicinal Chemistry Approaches for the Inhibition of the p38 MAPK Pathway

Stefan Laufer L., Simona Margutti, Dowinik Hauser

9.1

Introduction

The MAP kinases are a family of enzymes that participate in many cellular activities and are divided into three subfamilies: (1) The extracellular signal-related kinases (ERKs) that are widely expressed and that typically regulate cellular proliferation and differentiation. (2) The c-Jun-N-terminal kinases (JNKs) play a major role in extracellular matrix regulation through the production of metalloproteinases [1]. (3) p38 MAP kinase has four isoforms (α , β , γ , and δ) and plays an especially important role in the production of cytokines such as interleukin-1 (IL-1), tumor necrosis factor alpha (TNF- α), and IL-6 [2]. p38 MAP kinase, its central role in numerous proinflammatory cellular responses and the approaches of its inhibition by "small-molecule" chemical entities is the subject of this chapter.

The p38 mitogen-activated protein kinase (p38 MAPK) is known under several other names such as cytokine suppressive anti-inflammatory drug binding protein (CSPB) [3], stress-activated protein kinase 2 (SAPK2), and mHOG1 protein which is a yeast analogue encoded by the budding yeast HOG1 gene that is activated in response to hyperosmolarity.

9.2

p38 MAP Kinase Basics

The p38 MAP kinases are widely expressed in many cell types, including immune, inflammatory, and endothelial cells. Originally described as a 38 kDa polypeptide that underwent Tyr phosphorylation in response to endotoxin treatment and osmotic shock [4], p38 (the α -isoform) was purified by anti-phosphotyrosine immunoaffinity chromatography; p38 α is 50% identical to ERK2 and bears significant identity to the yeast kinase Hog1p involved in the response to hyperosmolarity [5, 6].

The p38 α -isoform has been associated most closely to inflammatory responses. A variety of factors, including stress, endotoxin, cytokines such as TNF- α and

Protein Kinases as Drug Targets. Edited by B. Klebl, G. Müller, and M. Hamacher
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 978-3-527-31790-5

Rheumatische Erkrankungen und Entzündung

Von den molekularen Grundlagen zur medikamentösen Therapie

Stefan Laufer
Steffen Gay
Kay Brune



Thieme

17

2 Biochemie und Mediatoren der Entzündung

Stefan Laufer

Inflammation and Rheumatic Diseases

The molecular basis of novel therapies

Stefan Laufer
Steffen Gay
Kay Brune



 Thieme

2 Biochemistry and Mediators of Inflammation

Fiorella Calanni, Stefan Laufer

DE GRUYTER

H.P.T. Ammon (Hrsg.)

HUNNIUS PHARMAZEUTISCHES WÖRTERBUCH

10. AUFLAGE

DE
G



Mitarbeiter dieser Auflage

Autoren

Prof. Dr. Hermann F. T. Ammon
Eberhard Karls Universität Tübingen
Fakultät für Chemie und Pharmazie
Pharmazeutisches Institut
Auf der Morgenstelle 8
D-72076 Tübingen

Dr. Andreas Bihlmayer
Regierungspräsidium Tübingen
Konrad-Adenauer-Straße 20
D-72072 Tübingen

Dr. med. P. Klaus Gonnert
Institut für Integrative Medizin
Hochwiesenstraße 13
A-5203 Köstendorf

Dipl. Chem. Markus Ehni
Eberhard Karls Universität Tübingen
Institut für Physikalische und
Theoretische Chemie
Auf der Morgenstelle 18
D-72076 Tübingen

Dr. Beate Firla
Centre Coordination
GRADE – Goethe Graduate Academy
Campus Riedberg
Riedbergplatz 1
D-60438 Frankfurt am Main

O. Univ.-Prof. Dr. phil. Ernst Haslinger
Karl-Franzens-Universität Graz
Institut für Pharmazeutische Wissenschaften
Pharmazeutische Chemie
Universitätsplatz 1
A-8010 Graz

Prof. Dr. Ulrich Jachde
Rheinische Friedrich-Wilhelms-Universität Bonn
Pharmazeutisches Institut
Klinische Pharmazie
An der Immenburg 4
D-53121 Bonn

Prof. Dr. Stefan Laufer
Eberhard Karls Universität Tübingen
Pharmazeutisches Institut
Auf der Morgenstelle 8
D-72076 Tübingen

Dr. Nicolas Lembert
Eberhard Karls Universität Tübingen
Pharmazeutisches Institut
Auf der Morgenstelle 8
D-72076 Tübingen

Dr. Hans-Peter Lipp
Eberhard Karls Universität Tübingen
Universitätsapotheke
Röntgenweg 9
D-72076 Tübingen

Prof. Dr. Hans-Jürgen Machulla
Eberhard Karls Universität Tübingen
Universitätsklinikum
Sektion für Radiopharmazie
Röntgenweg 15
D-72076 Tübingen

Mag. pharm. Dr. Elisabeth Nogler-Semenitz
TLAX – Tiroler Landeskrankenanstalten GmbH
Landeskrankenhaus Innsbruck
Anstaltsapotheke
Anichstraße 35
A-6020 Innsbruck

Dr. rer. nat. Elfriede Nusser-Rothermundt
Geislingerstraße 19
D-73312 Geislingen an der Steige


Dr. rer. nat. habil. Klaus Raith
Landesamt für Verbraucherschutz
Sachsen-Anhalt
Dezernat 24 – Arzneimittelprüfstelle
Wallonenberg 2–3
D-39104 Magdeburg

Prof. Dr. Jürgen Reichling
Universität Heidelberg
Institut für Pharmazie und Molekulare
Biotechnologie
Abteilung Biologie
Im Neuenheimer Feld 364
D-69120 Heidelberg

Prof. Dr. Peter Ruth
Eberhard Karls Universität Tübingen
Pharmazeutisches Institut
Auf der Morgenstelle 8
D-72076 Tübingen

Dr. sc. nat. Herbert Schatzmann
Aarehalde 16
CH-3047 Brenzgarten

Prof. Mag. pharm. Dr. rer. nat.
Wolfgang Schlocker
Universität Innsbruck
Institut für Pharmazie
Pharmazeutische Technologie
Innrain 52
A-6020 Innsbruck



CHAPTER 6

EFFICACIOUS ANTI-INFLAMMATORY AND RESPIRATORY DRUGS: DEVELOPMENTS FROM 1965 TO 2014

Peter R Bernstein
PharmB LLC, Rose Valley, Pennsylvania, U.S.A.

Stefan A. Laufer
Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy,
University of Tuebingen, Tuebingen, Germany

Contents

1. Introduction	138
2. Arachidonic Acid	139
2.1 Inflammation and the Prostaglandin (COX) Pathway	139
2.2 Pulmonary and Inflammatory Aspects of Lipoxygenase Pathway	141
2.3 Other Targets in the AA-cascade	143
3. Glucocorticoids	143
3.1 Mode of Action	143
3.2 History of Glucocorticoids	143
3.3 Local Administration	145
3.4 Inhaled Corticosteroids	145
4. Kinases/Phosphodiesterases/Sphingosine Modulators	147
4.1 JAK Inhibitors	150
4.2 PI3K Inhibitors	153
4.3 PDE4 Inhibitors	154
4.4 SIP Modulators	157
5. Non-AA Related GPCRs	157
5.1 β_2 -agonists	157
5.2 Anti-Cholinergics	161
5.3 Combination Agents	162
6. Mast Cell Stabilizers for Asthma	164
7. Conclusions	165

2015 Medicinal Chemistry Reviews, Volume 50
ISBN 978-0-9562532-0-4

© 2015 MEDI INC.
All rights reserved.

137

Others:

Springer Protocolls: Kinase Screening and Profiling

RSC Drug Discovery Series No. 40,
Macrocycles in Drug Discovery

Comprehensive Medicinal Chemistry III,

8.17 Are Two Better Than One in Rheumatoid Arthritis? Development of Dual p38a MAPK/PDE-4 Inhibitors for Treatment of TNFa-Driven Diseases